Inclusion Criteria:

          -  Previously untreated therapy-related AML or AML with myelodysplastic related changes
             as described by World Health Organization (WHO) 2016

               1. AML arising in MDS (including CMML) or MDS/MPN syndrome

               2. AML with MDS-related cytogenetic abnormalities (Appendix A, metaphase FISH
                  allowable as surrogate for cytogenetics)

               3. AML with multi-lineage dysplasia involving the presence of 50% or more dysplastic
                  cells in at least two cell lines and in the absence of mutation in NPM1 or
                  biallelic CEBPA (as per WHO 2016)

          -  Adults 18 years of age or older

          -  ECOG performance status 0 to 2

          -  Adequate organ function as defined as:

               1. Left Ventricular Ejection Fraction (LVEF) > 50%

               2. Serum total bilirubin < 2.0 mg/dL, unless considered due to Gilbert's disease or
                  leukemic involvement

               3. AST, ALT and alkaline phosphatase < 3 times the upper limit of normal, unless
                  considered due to leukemic involvement

               4. Serum creatinine < 2.0 mg/dL, or creatinine clearance > 40 mL/min based on
                  Cockcroft-Gault GFR

          -  Absence of unstable cardiac disease defined as myocardial infarction within 6 months,
             uncontrolled heart failure, or uncontrolled cardiac arrhythmia

          -  Ability to understand and the willingness to sign a written informed consent or
             subject's legally authorize representative (LAR) has provided informed consent prior
             to any study-specific activities/procedures being initiated when the subject has any
             kind of condition that, in the opinion of the investigator, may compromise the ability
             of the subject to give written informed consent

          -  Women of child-bearing potential and men with partners of child-bearing potential must
             agree to use 2 methods of birth control or be surgically sterile, or abstain from
             heterosexual activity for the course of the study through 120 days after the last dose
             of study medication

               1. A woman of child-bearing potential is any female (regardless of sexual
                  orientation, having undergone a tubal ligation, or remaining celibate by choice)
                  who meets the following criteria:

                    1. Has not undergone a hysterectomy or bilateral oophorectomy; or

                    2. Has not been naturally postmenopausal for at least 12 consecutive months
                       (i.e., has had menses at any time in the preceding 12 consecutive months)

               2. Women of child-bearing potential has negative pregnancy test within 72 hours of
                  initiating study drug dosing

               3. Male subjects must agree to use a latex condom during sexual contact with females
                  of childbearing potential even if they have had a successful vasectomy starting
                  with the first dose of study therapy through 120 days after the last dose of
                  study therapy

          -  Leukapheresis, corticosteroid and hydroxyurea are permitted as initial management of
             hyperleukocytosis at the investigator's discretion for up to 7 days after starting
             study therapy. Hyperleukocytosis is defined as greater than 30k WBC. When possible, a
             bone marrow biopsy for screening should be performed prior to the initiation
             hyperleukocytosis

        Exclusion Criteria:

          -  Prior treatment with Glasdegib or CPX-351

          -  Previously treated AML except for initial management of hyperleukocytosis. Treatment
             with hypomethylating therapy for MDS is allowable but not since their diagnosis of
             AML. No prior treatment with cytarabine or daunorubicin are allowed

          -  Concurrent FLT3 mutation that the treating physician deems necessary to treat with
             midostaurin, whereas patients with FLT3-mutated AML not treated with midostaurin can
             be enrolled. Patients with known Core Binding Factor -t(8;21), inv(16), t(16;16) are
             allowed for study participation at the treating investigator's discretion

          -  Active CNS or testicular involvement by leukemia; diagnostic lumbar puncture is not
             required

          -  History of neurologic disorder including but not limited to: prior seizure, epilepsy,
             structural brain abnormality, benign brain tumor, stroke, brain injuries, dementia,
             movement disorder or other significant CNS abnormalities

          -  Baseline QT corrected interval based on Fridericia's formula (QTcF) interval > 450 ms

          -  Acute coronary syndrome in the past 12 months, NYHA class III or VI

          -  Known history of Wilson's disease or other copper handling disorder

          -  History of GI malabsorptive disease

          -  Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
             skin, or in situ cervical cancer that has undergone potentially curative therapy

          -  Known HIV infection

          -  Active hepatitis B or hepatitis C infection (patients who successfully completed
             curative hepatitis C therapy can be enrolled)

          -  Any uncontrolled infection, active bacterial or viral infection manifesting as fevers
             or hemodynamic instability within the past 72 hours

          -  Proven active invasive fungal infection

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment

          -  Severe or uncontrolled medical disorder that would, in the investigator's opinion,
             impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal
             disease, chronic pulmonary disease or active, uncontrolled infection, psychiatric
             illness/social situations that would limit compliance with study requirements

          -  Current or anticipated use of other investigational agents

          -  For patients with prior anthracycline exposure, the cumulative life-time dose should
             not exceed 386mg/m2 at the time of study entry (to convert different anthracycline to
             daunorubicin-equivalent, see Appendix H for conversion factors)